The investigator's long-term goal is to conduct Naloxone for Opioid Associated out of Hospital Cardiac Arrest (NOPACA), a randomized, double blind, controlled trial to determine the efficacy of naloxone vs. placebo in Opioid Associated out of Hospital Cardiac Arrest. The investigative team plan to randomize patients in OHCA to early naloxone administration vs. placebo after initial resuscitation and measure ROSC and survival. Challenges to designing NOPACA include uncertainty regarding: 1) the available pool of participants and number of EMS agencies needed to meet enrollment targets; 2) acceptability among patients, EMS and Emergency Medicine provider stakeholders, and 3) estimates of the study outcomes needed for sample size estimates. Toward obtaining the necessary information to design NOPACA, the investigators propose a pilot RCT of participants at high risk for OA-OHCA to verify a reasonable recruitment rate; treatment fidelity and acceptability; and adequate retention and measurement of outcomes at follow up. The investigators propose incorporating hypothesis testing of the feasibility outcomes to determine progression to a definitive trial.

开始日期2026-11-01

申办/合作机构

The University of California, San Francisco

NCT04650841

/ Not yet recruiting早期临床1期IIT

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.

开始日期2025-09-01

申办/合作机构

Trustees of Dartmouth College

NCT07022717

/ Not yet recruitingN/AIIT

A Universal Primary Care Based Pilot Intervention to Reduce Youth Overdose Risk

Adolescent (ages 10-19) overdose deaths are the third leading cause of pediatric death and continue to rise in the United States. Healthcare providers have regular and trusted relationships with youth and have experience in providing public health injury prevention counseling. Youth have different motivations for using drugs, and many who experience fatal overdose do not have a history of opioid use. Primary care pediatric providers regularly provide developmentally appropriate injury prevention counseling for leading causes of pediatric fatal and nonfatal injury such as drowning prevention and firearms safety. However, there are no recommended, evidence-based overdose prevention interventions for youth, including in health care settings, even though research supports pediatricians and youth-serving clinicians providing harm reduction strategies such as naloxone distribution and overdose education. Among adults, overdose prevention education reduces overdose, is cost-effective, and can be learned by laypersons. Content commonly includes awareness of fentanyl in the drug supply, risk reduction (e.g., not using alone, risks of polysubstance use), and how to recognize and respond to an overdose, including the use of naloxone.
This study is a pilot two-arm cluster randomized controlled trial (RCT) of a brief overdose prevention education intervention that will be developed in collaboration with the Community Advisory Board (CAB). The primary outcome of this study is to assess the feasibility and acceptability of the brief youth overdose prevention intervention as measured by provider feasibility and acceptability as well as youth acceptability.

开始日期2025-07-01

申办/合作机构

Boston Medical Center

[+1]

100 项与盐酸纳洛酮相关的临床结果

登录后查看更多信息

100 项与盐酸纳洛酮相关的转化医学

登录后查看更多信息

100 项与盐酸纳洛酮相关的专利（医药）

登录后查看更多信息

30,721

项与盐酸纳洛酮相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients

Review

作者: Sheng, Nan ; Wu, Jianbing ; Fang, Fang ; Duan, Zhimin ; Li, Chengrang ; Xu, Beilei ; Song, Hao ; Zheng, Junyou

BACKGROUND:

Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.

OBJECTIVE:

To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.

METHODS:

Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.

RESULTS:

Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.

CONCLUSION:

Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.

2025-12-31·Future Science OA

Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model

Article

作者: Alzaghari, Lujain F. ; Qnais, Esam Y. ; Al-Najjar, Mohammad A. A. ; Barakat, Muna ; Chellappan, Dinesh Kumar ; Alqudah, Abdelrahim ; Athamneh, Rabaa Y.

AIMS:

To evaluate the analgesic and neuroprotective effects of cytidine, uridine, and gabapentin-administered alone and in combination-in models of diabetic neuropathy and formalin-induced acute and inflammatory pain.

MATERIALS & METHODS:

Oral doses of cytidine, uridine, and gabapentin (100 mg/kg each) were administered to rats with streptozotocin-induced diabetic neuropathy and in a formalin test model. Behavioral responses were recorded at 30, 60, and 120 minutes following treatment after five weeks of diabetes induction. Spinal cord p-CREB expression was measured to assess molecular changes, and pretreatments with naloxone, yohimbine, and methysergide were employed to explore opioid, adrenergic, and serotonergic contributions.

RESULTS:

All treatments significantly reduced formalin-induced pain in both acute and inflammatory phases (p < 0.05; p < 0.001) and increased mechanical pain thresholds in the diabetic neuropathy model at all-time points (p < 0.05). Combination therapy proved more effective than gabapentin alone (p < 0.05) and was associated with decreased spinal p-CREB levels, indicating altered anti-nociceptive signaling.

CONCLUSIONS:

The combined use of cytidine, uridine, and gabapentin enhances analgesia and neuroprotection compared to monotherapy, supporting its potential as a novel, analgesic-free treatment strategy for diabetic neuropathy.

2025-09-01·JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Lipopolysaccharide-induced abdominal nociception behavioral model in adult zebrafish (Danio rerio)

Article

作者: da Silva, João Gabriel Leite ; Bezerra, Franciglauber Silva ; Campos, Adriana Rolim ; Lima, Lorena Silva ; de Azevedo, Djane Ventura ; Batista, Francisco Lucas Alves ; da Silva, Larissa Morais Ribeiro ; Batista, Antonio Gustavo de Almeida ; Cavalcante Sobrinho, Francisco Bastos ; Guedes, Maria Izabel Florindo ; Coutinho, Henrique Douglas Melo ; Magalhães, Francisco Ernani Alves ; Moura, Luiz Francisco Wemmenson Gonçalves ; do Nascimento, Gabriela Alves ; de Sousa, Daniela Braga ; Farias-Pereira, Renalison ; de Araújo, Sandra Maria Barbosa ; de Oliveira, Maria Rayane Correia ; de Oliveira, Keciany Alves ; Coelho, Paulo Adenes Teixeira ; Raposo, Ramon da Silva ; Santos, Sacha Aubrey Alves Rodrigues

In this study a behavioral model of LPS-induced abdominal nociception was developed on adult zebrafish (Danio rerio), aZF. Initially, the toxicity of different LPS concentrations was assessed. The abdominal nociceptive response to the lowest LPS concentration was then analyzed, and the impact of sex on this nociceptive response was evaluated. The behavioral model of abdominal nociception was defined using the antinociceptive effects of morphine and diclofenac sodium. The mechanism of the possible involvement of TRPA1 in LPS-induced abdominal nociception was evaluated using HC-030031. Additionally, was investigated whether naloxone could modulate morphine's antinociceptive effect. The Light & Dark Test was conducted to assess any potential anxiolytic-like effect of LPS. The Open Field Test was performed to evaluate the possible sedative effect/or not of morphine and diclofenac sodium. As a result, the tested LPS endotoxin solutions were not endotoxic against aZF (LC₅₀>0.25 mg/mL). LPS significantly increased the abdominal nociceptive behavior of aZF. Sex did not affect the response profile to the endotoxin. Morphine and diclofenac sodium inhibited abdominal nociception induced by LPS and the effect of morphine was blocked by naloxone. HC-030031 significantly inhibited abdominal nociception induced by LPS. The LPS did not cause an anxiolytic-like effect. Morphine and diclofenac sodium did not affect the locomotion of the animals. The results suggest that aZF can be used as a behavioral model of abdominal nociception induced by LPS endotoxin.

601

项与盐酸纳洛酮相关的新闻（医药）

2025-06-11

·PRNewswire

Elysium Therapeutics' Investor Webcast Highlights "Fentanyl Rebound" as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Elysium's Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology designed specifically to combat oral fentanyl overdose LYONS, Colo., June 11, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, recently hosted a webcast to educate investors and pharmaceutical leaders on the pressing need to develop overdose rescue therapies designed specifically for synthetic opioids, like fentanyl. Entitled, "Innovating Solutions to Combat Fentanyl Rebound" and led by Greg Sturmer, CEO, the presentation noted that short-acting opioid antagonists like Narcan® and Opvee® are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. Sturmer commented: "When fentanyl is taken orally, individuals can face a danger zone, a period of respiratory depression that can last six to eight hours, which far outlasts the window provided by currently available rescue agents that only last, at most, 30 minutes. The result is nearly half of those initially given a dose of today's rescue medications experience a rebound or re-narcotization event, which can lead to a hypoxic brain injury, cardiovascular toxicity or death." To address this critical shortcoming, Elysium designed its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology to be both faster acting and with the potential to offer overdose protection out to approximately 24-hours. Additionally, Elysium designed SOOPR with an intramuscular route of administration, which grants more reliable dosing, in comparison to intranasal administration, which can lead to partial and uncertain dosing in high stress settings. Sturmer added: "SOOPR was designed specifically for synthetic opioids, which are now the number one killer of adults aged 18 to 45 in the U.S. The need for a rapid-acting, long-duration reversal agent, such as SOOPR, is extreme given its potential to reduce the likelihood of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Recognizing this opportunity, Elysium is planning to rapidly advance the SOOPR clinical program along a timeline that could enable the technology to reach the market in the next two to three years." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . ¹ Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88. SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-06-06

·PRNewswire

Victoria's Voice Foundation Marks National Naloxone Awareness Day on June 6 with Special Event on Capitol Hill

Annual Awareness Day Focusing Attention on the Drug Crisis and Importance of Lifesaving Opioid Overdose Reversal Medications was Launched by Victoria's Voice with Support from a Bipartisan Congressional Resolution Over 140 Iconic Buildings and Landmarks Nationwide to Shine Purple in Recognition of Awareness Day WASHINGTON, June 6, 2025 /PRNewswire/ -- Victoria's Voice Foundation marked National Naloxone Awareness Day on June 6 with a special event on Capitol Hill, bringing together families affected by the opioid crisis, advocates, lawmakers, law enforcement and other first responders. The awareness day is a vital time to heighten awareness of the risks of opioid overdoses and the urgency of expanding access to and the use of lifesaving overdose reversal medicines. It was launched in 2023 by Victoria's Voice Foundation with support from a bipartisan congressional resolution recognizing the awareness day annually. Naloxone, commonly sold over the counter under the brand name NARCAN® Nasal Spray, is a critical tool in preventing fatal opioid overdoses – and is credited with helping drive the recent 27% decline in U.S. drug overdose deaths. Naloxone nasal spray helps restore normal breathing in a person experiencing an opioid overdose. It is safe, easy to administer and non-addictive – and designed for use by bystanders and first responders alike. This is crucial because nearly 40% of fatal overdoses occur in the presence of someone else, according to the CDC. "We must continue to expand naloxone awareness, access and use so we can save as many lives as possible from opioid overdose," said Jackie Siegel, who co-founded Victoria's Voice with her late husband, David, after losing their daughter, Victoria, 18, to an accidental drug overdose on June 6, 2015. On the day she died, Victoria had a pulse when first responders arrived and found her unresponsive, but they were not equipped with naloxone, and Victoria became another statistic. Jackie added: "I am deeply grateful to the members of the U.S. Senate who introduced a bipartisan resolution declaring June 6 as National Naloxone Awareness Day – and to all those on the front lines of the crisis. While today is especially bittersweet as we mark 10 years since Victoria's passing, I find comfort and strength in knowing that her legacy is that because of her death, many more people will live." Victoria's Voice is dedicated to drug awareness and prevention and saving lives from overdose. Since its founding, Victoria's Voice has positively impacted over 1.5 million children and parents through its education programs. Additionally, David Siegel was at the forefront of the efforts to increase naloxone access and use – especially among law enforcement in Florida and nationwide – and inform about its lifesaving power. The 2025 federal resolution was introduced by U.S. Senators Rick Scott (R-FL), Ed Markey (D-MA), Jim Justice (R-WV), Maria Cantwell (D-WA), Ashley Moody (R-FL), Sheldon Whitehouse (D-RI), James Lankford (R-OK), Ron Wyden (D-OR), Angus King (I-ME) and Raphael Warnock (D-GA). Speakers at yesterday's resolution ceremony in the Hart Senate Office Building included Jackie Siegel, Sen. Rick Scott (R-FL), and Seminole County (FL) Sheriff Dennis Lemma, a statewide and national leader on responding to and preventing overdoses, and a Victoria's Voice board member. Other speakers included Sen. Ashley Moody (R-Fl), Rep. Sharice Davids (D-KS), Virginia First Lady Suzanne S. Youngkin, and Sir Edwards, Mayor-President of Baton Rouge (LA). "It is a privilege to join Victoria's Voice Foundation in recognizing National Naloxone Day and honor the life of Victoria, a young life lost to the devastating opioid epidemic. It is every parent's worst nightmare to lose their child, and it is remarkable to see how the Siegel family has turned their grief into a mission to educate others about the dangers of the opioid crisis so other families don't experience this same heartbreak," said Sen. Rick Scott (R-FL). Scott added: "This year was also the first Naloxone Awareness Day since the passing of my friend and Victoria's Voice founder, David Seigel. Ann and I were honored to donate a portion of my Senate salary to Victoria's Voice to support its cause and pay tribute to David's incredible work and legacy. I am proud to work with the foundation to raise awareness on the crisis and life-saving tool of Naloxone, which is critical in our fight to stop loss of life from opioids." "In every state, there are families, friends, and neighbors who are grieving the loss of a loved one to overdose. Naloxone can save lives but only if we get this lifesaving medication in people's hands. We need people to have access to naloxone, be able to afford it, and know how to use it," said Senator Ed Markey (D-MA). "I'm proud to join my colleagues in recognizing June 6 as Naloxone Awareness Day. This is an essential step in spreading awareness and giving communities the tools they need to save lives in the face of the opioid epidemic." National Naloxone Awareness Day is proudly sponsored by Emergent BioSolutions, the makers of NARCAN® Nasal Spray. "On National Naloxone Awareness Day, we have the opportunity to reinforce opioid emergency preparedness and make sure stakeholders across all sectors – from government officials to business leaders and local organizations – feel equipped with the tools they need to be ready to rescue not only today, but every day," stated Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "We're proud of the work Victoria's Voice Foundation is doing year-round and we're honored to use this key moment in time to raise awareness and keep our communities safe together." In support of National Naloxone Awareness Day, over 140 iconic buildings, landmarks, bridges, monuments, parks, museums, city halls, downtown hubs and skylines nationwide will glow purple. From Niagara Falls, Baltimore's City Hall Dome, and the Kia Center in Victoria's Voice's Orlando hometown, to the Louisiana State Capitol, Chicago's 875 North Michigan Avenue and the Hawaii Convention Center, lights will be illuminated purple in a powerful display of awareness, unity and hope. Additionally, proclamations were issued by counties, cities and states including Orange County (FL), Baltimore, Kansas City, and the State of Illinois. For more information about National Naloxone Awareness Day, visit . About Victoria's Voice Foundation David and Jackie Siegel established Victoria's Voice Foundation after losing their 18-year-old daughter to an accidental drug overdose on June 6, 2015. Victoria's Voice is dedicated to providing support and resources to families affected by substance use. Since its founding, Victoria's Voice has positively impacted over 1.5 million parents and children through its education programs. For more information, visit or @victoriasvoicefoundation. #VictoriasVoiceFoundation #GetGiveSave. About NARCAN® Nasal Spray NARCAN® Naloxone HC1 Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed. SOURCE Victoria’s Voice Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-06-05

·GlobeNewswire-Health Care

Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria’s Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria’s Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple light bulb (Shine), a wearable promotional item (Wear), a QR code encouraging participation in the #sharenaloxone social media campaign (Share) and a box of NARCAN® Nasal Spray (Care) provided by Emergent. "It’s been 10 years since our Victoria lost her life to an accidental opioid overdose and we remain fiercely committed to honoring her memory and the memory of others who have succumbed to this same tragedy by fostering open dialogue about the dangers of opioids and precautionary safety measures, so other families don’t have to experience the same tragedy," said Jackie Siegel, of Victoria's Voice Foundation. "We’re pleased that Emergent is our sponsor for this year’s National Naloxone Awareness Day to further our shared mission of saving as many lives as possible through naloxone education and distribution." The Centers for Disease Control and Prevention recently announced a nearly 27 percent decrease in drug overdose deaths in 2024, with opioid-related deaths dropping by 34 percent from 2023.1 Several factors have likely contributed to this decline – one of them being increased access to over the counter (OTC) intranasal naloxone, including the first U.S. FDA-approved option, NARCAN® Nasal Spray. This life-saving medication is designed to rapidly reverse an opioid poisoning in minutes, giving more people the power to save a life in an opioid emergency. While this data signals a promising step forward, there is more work to be done as opioid overdoses are still the leading cause of accidental death in the U.S.2 Emergent is committed to increasing awareness and access about NARCAN® Nasal Spray across as many communities as possible to ensure everyone has the power to save a life. With the Ready to Rescue initiative, Emergent tackles the pervasive stigma associated with opioid overdose and offers opioid emergency preparedness education to young adults and communities across the country. Emergent is also partnering with businesses and organizations so NARCAN® Nasal Spray will be more accessible for people across industries. "On National Naloxone Awareness Day, we have the opportunity to reinforce opioid emergency preparedness and make sure stakeholders across all sectors – from government officials to business leaders and local organizations – feel equipped with the tools they need to be ready to rescue not only today, but every day," stated Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We’re proud of the work Victoria’s Voice Foundation is doing year-round and we’re honored to use this key moment in time to raise awareness and keep our communities safe together.” Emergent demonstrates its commitment to protect and save lives by distributing prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, in addition to OTC NARCAN® Nasal Spray, and remains steadfast in expanding access to multiple options of nasal naloxone for patients, caregivers, first responders, and communities who are confronting the impact of the opioid epidemic. For more information about National Naloxone Awareness Day and how to get involved, visit VictoriasVoice.foundation. To learn more about how you can access NARCAN® Nasal Spray and be prepared to save a life, visit NARCAN.com. About NARCAN® Nasal SprayNARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed. Important Safety Information for KLOXXADO® (naloxone HCl) Nasal Spray 8 mg What is KLOXXADO® Nasal Spray? KLOXXADO® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.KLOXXADO® Nasal Spray is to be given right away and does not take the place of emergency medical care.Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray, even if the person wakes up. What is the most important information I should know about KLOXXADO® Nasal Spray?Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received. The medicine in KLOXXADO® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO® Nasal Spray is not intended for self-administration. What should I tell my healthcare provider (pharmacist or prescriber) before using KLOXXADO® Nasal Spray?Before using KLOXXADO® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you: have heart problemsare pregnant or plan to become pregnant. Use of KLOXXADO® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO® Nasal Spray.are breastfeeding or plan to breastfeed. It is not known if KLOXXADO® Nasal Spray passes into your breast milk. What are the possible side effects of KLOXXADO® Nasal Spray?KLOXXADO® Nasal Spray may cause severe opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure. In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes. Who should not use KLOXXADO® Nasal Spray?Do not use KLOXXADO® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO® Nasal Spray. What are the most common side effects of KLOXXADO® nasal spray?The most common side effects of KLOXXADO® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint. These are not all of the possible side effects of KLOXXADO® Nasal Spray. Please see full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects. You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364. Trademarks and logos are the property of their respective owners. About Victoria’s Voice Foundation David and Jackie Siegel established Victoria’s Voice Foundation after losing their 18-year-old daughter to an accidental drug overdose on June 6, 2015. Victoria’s Voice is dedicated to providing support and resources to families affected by substance abuse. Since its founding, Victoria’s Voice has positively impacted more than 1.5 million parents and children through its education programs. For more information about Victoria’s Voice, visit www.victoriasvoice.org or @victoriasvoicefoundation. #VictoriasVoiceFoundation #GetGiveSave. About Emergent BioSolutionsAt Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com __________________________1 https://www.cdc.gov/nchs/pressroom/releases/20250514.html2 https://www.cdc.gov/nchs/fastats/accidental-injury.htm

100 项与盐酸纳洛酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01340	盐酸纳洛酮	A06AH04 V03AB15	DB01183

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性淋巴细胞白血病	加拿大	Hikma Pharmaceuticals LLC	2025-02-01
阿片类药物过量	美国	Emergent Devices, Inc.	1971-04-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿片滥用	临床前	美国	Consegna Pharma, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03751111 (CTgov)	临床1/2期	瘙痒 \| 肛门瘙痒	126	Naloxone (Naloxone)	糧構願獵襯鏇齋壓繭願(選醖積構範範遞獵憲衊) = 鑰糧鬱淵築艱獵選膚鏇蓋餘獵淵鏇膚範齋壓夢 (醖醖鑰構顧願鹽壓膚憲, 2.15) 更多	-	2025-04-20
				Placebo (Placebo)	糧構願獵襯鏇齋壓繭願(選醖積構範範遞獵憲衊) = 蓋製願鹹醖廠鹹繭艱憲蓋餘獵淵鏇膚範齋壓夢 (醖醖鑰構顧願鹽壓膚憲, 1.99) 更多
NCT04473950 (CTgov)	临床1期	阿片相关性障碍 \| 慢性疼痛	10	Placebo+Naloxone Hydrochloride (Pain Group)	壓觸膚壓醖餘廠夢齋構(蓋襯齋築憲廠鹹顧窪憲) = 窪餘構艱艱鏇鏇積鹹憲憲壓製選艱齋遞積膚襯 (獵範鏇鏇製蓋製製鹽獵, 1.17) 更多	-	2025-03-26
				Placebo+Naloxone Hydrochloride (No Pain Group)	壓觸膚壓醖餘廠夢齋構(蓋襯齋築憲廠鹹顧窪憲) = 製遞糧蓋醖顧觸艱壓膚憲壓製選艱齋遞積膚襯 (獵範鏇鏇製蓋製製鹽獵, 0.92) 更多
NCT03176316 (FusionIleus, CTgov)	临床4期	肠阻塞	53	Naloxone	選襯選獵齋餘醖繭網淵 = 鹽壓構淵糧窪壓醖築網製襯憲艱選築襯糧選積 (選獵築網網餘襯淵餘鏇, 製觸築積製壓簾糧繭鏇 ~ 膚壓築獵獵襯鏇網憲醖) 更多	-	2024-07-01
NCT03149770 (CTgov)	临床2期	1型糖尿病 \| 低血糖	30	Naloxone (Naloxone)	鬱醖築壓鏇構繭襯觸觸(廠憲網積鏇膚膚壓鏇鹹) = 餘選憲齋鬱齋範範糧蓋願淵遞構繭鑰衊網顧繭 (鑰糧衊獵遞選醖夢蓋襯, 12) 更多	-	2024-04-16
				placebo (Placebo)	鬱醖築壓鏇構繭襯觸觸(廠憲網積鏇膚膚壓鏇鹹) = 簾獵廠齋壓積蓋鏇艱鏇願淵遞構繭鑰衊網顧繭 (鑰糧衊獵遞選醖夢蓋襯, 13) 更多
NCT04764630 (Pubmed \| JAMA Netw Open)	临床1期	阿片类药物过量	21	1 dose at 0, 2.5, 5, and 7.5 minutes	膚鏇襯艱獵遞膚衊築夢(網積遞廠廠醖膚齋廠築) = 夢選願糧觸鬱網蓋膚醖鏇衊築鹽廠憲膚淵積餘 (繭膚糧淵衊鏇網鹹製鹹 )	-	2024-01-23
				2 doses at 0 and 2.5 minutes	膚鏇襯艱獵遞膚衊築夢(網積遞廠廠醖膚齋廠築) = 繭鏇構構衊窪餘鹹齋獵鏇衊築鹽廠憲膚淵積餘 (繭膚糧淵衊鏇網鹹製鹹 )
NCT03570099 (Pubmed \| BMJ Open)	N/A	阿片类药物过量	-	Take-home naloxone distribution	鏇範範鏇顧鬱觸衊構膚(鏇願齋廠遞願艱蓋鹽蓋) = 醖廠簾築齋醖觸網選鏇襯糧顧淵鹽襯淵憲憲齋 (衊積積選齋簾艱構簾鹽 )	-	2024-01-01
				intranasal naloxone (Control period (2013-2017))	鏇範範鏇顧鬱觸衊構膚(鏇願齋廠遞願艱蓋鹽蓋) = 淵構獵醖憲廠顧獵簾衊襯糧顧淵鹽襯淵憲憲齋 (衊積積選齋簾艱構簾鹽 )
ADA2023	N/A	单纯自主神经功能衰竭	-	Intranasal naloxone (IN)	簾襯淵構窪遞繭廠醖壓(廠簾鹽衊淵壓網遞製淵) = 顧膚鏇淵範顧膚積鹹築鏇鑰蓋鏇餘膚襯憲膚顧 (網蓋製艱夢衊衊顧艱鏇 ) 更多	-	2023-06-20
				Placebo	簾襯淵構窪遞繭廠醖壓(廠簾鹽衊淵壓網遞製淵) = 憲蓋憲繭選選構艱網齋鏇鑰蓋鏇餘膚襯憲膚顧 (網蓋製艱夢衊衊顧艱鏇 ) 更多
NCT04713709 (Corporate Publications) 人工标引	临床1期	阿片类药物过量	56	FMXIN001	夢獵鑰簾廠選鑰願製築(夢餘艱夢齋簾蓋窪憲醖) = 遞壓網齋選壓膚願淵餘製選構壓齋衊襯簾獵簾 (齋築簾膚艱齋鹽願築鏇 ) 更多	相似	2022-07-28
				NARCAN	夢獵鑰簾廠選鑰願製築(夢餘艱夢齋簾蓋窪憲醖) = 遞壓繭齋膚觸齋膚選糧製選構壓齋衊襯簾獵簾 (齋築簾膚艱齋鹽願築鏇 ) 更多
NCT04764630 (CTgov)	临床1期	-	21	naloxone (A. Four Naloxone Nasal Spray Doses (1 Every 2.5 Min))	遞艱築顧鑰獵醖淵顧鬱(鬱獵顧簾顧蓋鏇網廠遞) = 積鹹鏇鑰網築醖廠衊艱蓋醖獵選構廠鹹觸餘襯 (淵醖簾鹽積淵遞鬱鑰選, 70) 更多	-	2022-07-15
				naloxone (C. Two Naloxone Nasal Spray Doses (1 Every 2.5 Min))	遞艱築顧鑰獵醖淵顧鬱(鬱獵顧簾顧蓋鏇網廠遞) = 壓網蓋鑰壓憲顧餘積膚蓋醖獵選構廠鹹觸餘襯 (淵醖簾鹽積淵遞鬱鑰選, 159) 更多
NCT02805972 (BEE, CTgov)	临床2期	肥胖	41	Placebo+Naloxone (Placebo, Then Naloxone)	壓襯築蓋願鹹醖壓蓋鏇(廠醖積網製鑰觸繭鹹襯) = 襯製觸鑰夢範夢遞繭膚鬱觸獵積鹽鹹獵積築艱 (醖築願鹹廠醖壓餘鏇艱, 鹽壓遞鏇淵範窪襯範艱 ~ 選醖膚築窪糧夢範膚壓) 更多	-	2021-11-03
				Placebo+Naloxone (Naloxone, Then Placebo)	壓襯築蓋願鹹醖壓蓋鏇(廠醖積網製鑰觸繭鹹襯) = 鹽蓋鬱網衊範醖夢鹹顧鬱觸獵積鹽鹹獵積築艱 (醖築願鹹廠醖壓餘鏇艱, 鬱餘淵憲願觸齋鏇顧獵 ~ 艱積鏇糧積範夢窪製淵) 更多